TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28164014
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary interventions (PCI) performed in 175 Russian PCI centers; 531 PCI per 1,000,000 population; 101,451 stents placed (1.37 stents per PCI; 48,057 drug-eluting stents).
Study: 28164367
Drug: Severe hyperglycaemia
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe hyperglycaemia (> 11.1 mmol/l) in people without diabetes
Study: 28166794
Drug: Malaria treatment
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malaria treatment or any other medication within 14 days
Study: 28166794
Drug: Insecticide spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insecticide spray within 7 days
Study: 28168735
Drug: Imiquimod (IMQ)
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod (IMQ) pretreatment with NB-UVB therapy
Study: 28168735
Drug: NB-UVB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB-UVB therapy alone
Study: 28169974
Drug: Biological parenteral
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological parenteral treatment
Study: 28169974
Drug: Nonbiological oral
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbiological oral treatment
Study: 28173784
Drug: Comprehensive approach
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive approach integrating clinical and functional status-based pathology and adapted rehabilitation prescription
Study: 28174148
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam for conscious sedation
Study: 28174191
Drug: Therapeutic ultrasound
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3) for 10 minutes after intravenous injection of microbubble contrast agents (2×10)
Study: 28174292
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin spray
Study: 28174487
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX)
Study: 28177438
Drug: TG4023 (MVA-FCU1)
Normalized name: MVA
DrugBank: TG4023 (DB06108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4023 (MVA-FCU1) at doses of 107, 108, or 4 × 108 p.f.u. via intratumoral injection
Study: 28177438
Drug: 5-FC (flucytosine)
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-FC (flucytosine) at a dose of 200 mg/kg/day for 14 days
Study: 28177438
Drug: TG4023/5-FC combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4023/5-FC combination
Study: 28177438
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with TG4023 and 5-FC
Study: 28178640
Drug: Alisertib (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) in combination with abiraterone and prednisone (AP)
Study: 28179030
Drug: Sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa (0.35 mg/kg with intrapatient dose escalation up to 5 mg/kg, once weekly)
Study: 28179439
Drug: Inhaled ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ATP
Study: 28179439
Drug: Inhaled AMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled AMP
Study: 28181118
Drug: Flutemetamol F
Normalized name: Flutemetamol F18
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flutemetamol F 18 Injection (185 MBq)
Study: 28181933
Drug: Severe intraoperative
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe intraoperative hyperglycemia (SIH, blood glucose ≥180 mg/dL)
Study: 28182762
Drug: High 2'FL
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 2'FL concentration (1880-2460 mg/L)
Study: 28182762
Drug: Low 2'FL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low 2'FL concentration (12-42 mg/L)
Study: 28183713
Drug: Vaccination targeting
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination targeting native receptors
Study: 28185288
Drug: Metformin (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2,000 mg/day for 9 or more days prior to surgery)
Study: 28186982
Drug: AvidinOX anchorage
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AvidinOX anchorage with biotinylated antibodies
Study: 28187404
Drug: Potentized estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentized estrogen (12cH, 18cH and 24cH) administered twice daily per oral route for 24 weeks
Study: 28188000
Drug: Structured program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured program for β-blocker titration with up-titration visits every 2 weeks after implantation (target dose: 10mg/day of bisoprolol or 50mg/day of carvedilol).
Study: 28188000
Drug: Remote monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote monitoring for 66 patients in Study Group with daily transmission of weight and blood pressure data.
Study: 28188239
Drug: No immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No immunosuppressant
Study: 28188773
Drug: Maternal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal buprenorphine administration
Study: 28188907
Drug: NEO6860 (TRPV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEO6860 (TRPV1 antagonist)
Study: 28190158
Drug: Ketamine mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine mouthwash 20 mg/5 mL four times daily
Study: 28190704
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (photon radiation therapy)
Study: 28191026
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g Flaxseed Fiber (FF) with Orlistat
Study: 28191026
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg Dairy Calcium (Ca) with Orlistat
Study: 28191034
Drug: Integrated treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatments plus a once-daily multivitamin
Study: 28192114
Drug: Sirolimus and
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus and hydroxychloroquine (200 mg twice a day)
Study: 28192114
Drug: Sirolimus and
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus and hydroxychloroquine (400 mg twice a day)
Study: 28192597
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg orally and daily on a continuous schedule)
Study: 28193194
Drug: Falls surveillance
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Falls surveillance with monthly calendars and telephone interviews
Study: 28193515
Drug: Not exposed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not exposed to biologics (Control)
Study: 28193678
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization protocol (5.5 hours)
Study: 28193678
Drug: Aspirin desensitization
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin desensitization protocol
Study: 28194232
Drug: Post-challenge OGTT
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-challenge OGTT 2 h insulin in CSX
Study: 28194232
Drug: Post-challenge OGTT
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-challenge OGTT 2 h insulin in CAD
Study: 28194232
Drug: Fasting glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose, insulin, HOMA-IR in CSX
Study: 28194232
Drug: Fasting glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose, insulin, HOMA-IR in CAD
Study: 28194539
Drug: Pimasertib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimasertib (45 mg/day) plus Temsirolimus (25 mg/week)
Study: 28196056
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX; Ozurdex 700 μg) administered immediately after cataract surgery
Study: 28196270
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly
Study: 28196715
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral cholera vaccine (OCV), Shanchol™
Study: 28196905
Drug: DHP107, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP107, a novel oral paclitaxel formulation, 200 mg/m
Study: 28196905
Drug: DHP107, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHP107, a novel oral paclitaxel formulation, 150-250 mg/m
Study: 28197031
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oral diclofenac 1 hour before procedure (Group A)
Study: 28199478
Drug: Topical carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carmustine and intravenous O6-benzylguanine
Study: 28199478
Drug: Dual-dose O6-benzylguanine
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dual-dose O6-benzylguanine plus carmustine
Study: 28199478
Drug: Single-dose O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose O6-benzylguanine and carmustine
Study: 28202056
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml 12.6% carbohydrate-rich drink
Study: 28202638
Drug: Single-Dose Supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-Dose Supplementation
Study: 28203424
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with paclitaxel and cisplatin plus McKeown esophagectomy with total two-field lymphadenectomy
Study: 28204726
Drug: Qutenza® (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qutenza® (topical capsaicin 8%)
Study: 28205038
Drug: Loxapine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxapine for inhalation
Study: 28205231
Drug: ctDNA presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA presence monitoring after chemotherapy
Study: 28207791
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations of 40 to 49.99 nmol/L
Study: 28207791
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations of 30 to 39.99 nmol/L
Study: 28207791
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations of <30 nmol/L
Study: 28207791
Drug: 25(OH)D concentrations
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25(OH)D concentrations of 75 to 99.99 nmol/L
Study: 28207791
Drug: High 25(OH)D
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High 25(OH)D levels up to 125 nmol/L
Study: 28207896
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with Serpinb6b (granzyme A inhibitor)
Study: 28209218
Drug: NOAC (non-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC (non-vitamin K antagonist oral anticoagulants)
Study: 28210662
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40)
Study: 28213596
Drug: Total white
Normalized name: Colgate Total Whitening
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total white cell count (WBC) within the normal range (8.65-10.05×10^9/L)
Study: 28213684
Drug: Community-based chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based chronic care overweight and obesity treatment
Study: 28213914
Drug: Chronic autonomic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS) at 10 Hz, 250 μs pulse width, 18% duty cycle, maximum tolerable current amplitude after 10 weeks of titration
Study: 28213914
Drug: Chronic autonomic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS)
Study: 28213943
Drug: Elotuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab (10 mg/kg, accelerated infusion over ∼1 h), combined with lenalidomide (25 mg daily, Days 1-21) and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1-2; 40 mg orally, weekly, Cycles 3+)
Study: 28213943
Drug: Elotuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab (10 mg/kg, standard infusion over ∼3 h), combined with lenalidomide and dexamethasone (from previous phase 3 study)
Study: 28214655
Drug: Eribulin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin treatment
Study: 28215251
Drug: Caffeine consumption
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine consumption in CC genotype
Study: 28215851
Drug: Neoadjuvant Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Stereotactic Body Radiotherapy (SBRT) at escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions
Study: 28215937
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg subcutaneously monthly (or every 2 weeks if on apheresis)
Study: 28215937
Drug: Evolocumab (increased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (increased dosing to every 2 weeks)
Study: 28218593
Drug: In-car video
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-car video feedback intervention (3 months of intervention with weekly reports, DVD of unsafe events, and telephone contacts)
Study: 28219694
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg per day for 21 of 28 days until lymphoma progression or unacceptable toxicity
Study: 28219925
Drug: Consistent long-term
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consistent long-term heavy alcohol intake >112 g of ethanol/week
Study: 28221823
Drug: MiniMed 640G
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiniMed 640G 'suspend before low' feature set at 65 mg/dL, predicting hypoglycemia and suspending insulin delivery when glucose was predicted to be ≤85 mg/dL.
Study: 28222073
Drug: Oral rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rucaparib (240 mg per day) combined with carboplatin (AUC 5 mg/ml)
Study: 28222073
Drug: Intravenous rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rucaparib combined with various chemotherapy regimens (carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, epirubicin/cyclophosphamide)
Study: 28225505
Drug: Conventional optimal
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional optimal medical therapy
Study: 28226404
Drug: Molecular scores
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular scores for antibody-mediated rejection, T cell-mediated rejection, and injury
Study: 28228461
Drug: Residual inflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual inflammatory risk (hsCRP >3 mg/L)
Study: 28229893
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg intravenous
Study: 28231807
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of direct and indirect measures of adiposity
Study: 28235011
Drug: Type of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of cancer therapy
Study: 28235771
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with histamine dihydrochloride (HDC) and low-dose IL-2
Study: 28235848
Drug: LQT2 patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LQT2 patients underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling.
Study: 28235848
Drug: Control participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control participants underwent the same 6-hour 75-g oral glucose tolerance test.
Study: 28238593
Drug: Lapatinib (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients received letrozole (2·5 mg per day orally) or tamoxifen (20 mg per day orally).
Study: 28238631
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of QHPV
Study: 28238631
Drug: 4 doses
Normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 doses of QHPV
Study: 28239491
Drug: Travoprost 0.004%/Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/Timolol 0.5% fixed-dose combination
Study: 28240822
Drug: Recombinant Sfrp3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Sfrp3 treatment in myotubes from lean insulin-sensitive subjects
Study: 28240822
Drug: LPS or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS or recombinant IL-6 treatment in in vitro-differentiated myotubes
Study: 28241770
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of tobacco use treatment guidelines using the Consolidated Framework for Implementation Research (CFIR)
Study: 28241807
Drug: High-dose external
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose external beam radiation therapy (RT)
Study: 28241824
Drug: Autologous Platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Platelet Rich Plasma (PRP) injections and topical application of PRP gel
Study: 28241824
Drug: Autologous Platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Platelet Rich Plasma (PRP) injections
Study: 28243404
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic therapy for CINV
Study: 28243577
Drug: Idursulfase treatment
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase treatment
Study: 28245821
Drug: Higher tertiles
Normalized name: textiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tertiles of GDF-15 (mean GDF-15 was 1,304 pg/mL)
Study: 28246291
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injections, 155 units administered every 12 weeks
Study: 28248702
Drug: Norepinephrine 3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 3, 4, 5, 6, 7, or 8 µg IV bolus
Study: 28249145
Drug: Lentiviral vector-mediated
Normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells; details on dosage and duration not available.
Study: 28249145
Drug: Busulfan conditioning;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan conditioning; details on dosage and duration not available.
Study: 28249841
Drug: Bivalent virus-like
Normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent virus-like particle (VLP) vaccine (GI.1/GII.4) administered intramuscularly.
Study: 28250200
Drug: Vismodegib (Hh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib (Hh inhibitor) treatment in cancer patients
Study: 28254126
Drug: CRT-ON (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-ON (Cardiac Resynchronization Therapy ON)
Study: 28254126
Drug: CRT-D (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D (Cardiac Resynchronization Therapy with defibrillator)
Study: 28254203
Drug: Minimal caregiver
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal caregiver worry about medication adverse effects
Study: 28254869
Drug: Selective radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective radiotherapy dose increase to hypoxic tumor areas, details on dosage and duration not specified.
Study: 28256358
Drug: MVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 29 (standard)
Study: 28256358
Drug: MVA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 15